FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140257324> ?p ?o ?g. }

• W2140257324 endingPage "1384" @default.
• W2140257324 startingPage "1378" @default.
• W2140257324 abstract "Androgen deprivation therapy is the primary treatment for advanced prostate cancer but many patients eventually experience progression to hormone refractory status. Understanding the molecular changes after androgen deprivation therapy would help evaluate the efficacy or failure of second line therapies. Therefore, we analyzed the expression of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN), the human epidermal receptor-2 and neuroendocrine differentiation after bicalutamide monotherapy, which is emerging as an alternative treatment for locally advanced prostate cancer.Molecular arrangements were evaluated in 107 radical prostatectomy specimens from patients given 150 mg bicalutamide before surgery. Pathological regressive changes, and the correlation of postoperative biochemical failure with the extent of molecular arrangements and pathological effects were analyzed.Patients with minimal regression effects after bicalutamide therapy had advanced pathological stage disease, and tended to have positive chromogranin A expression and PTEN inactivation. Only 4 (3.7%) prostatectomy specimens showed human epidermal receptor-2 immunostaining. The probability of positive chromogranin A expression in the PTEN inactivation group was 2.5-fold (OR 2.5, 95% CI 1.1-5.6, p = 0.023) higher than in the nonPTEN inactivation group. Cox regression analysis revealed that seminal vesicle invasion, PTEN/chromogranin A expression and lymph node invasion were significant variables for time to biochemical recurrence.PTEN inactivation and neuroendocrine differentiation were related to refractoriness to bicalutamide therapy. These results support the hypothesis that neuroendocrine differentiation is caused by activation of the serine threonine kinase Akt pathway, which results from PTEN inactivation." @default.
• W2140257324 created "2016-06-24" @default.
• W2140257324 creator A5016101715 @default.
• W2140257324 creator A5044840923 @default.
• W2140257324 creator A5054102028 @default.
• W2140257324 creator A5077481880 @default.
• W2140257324 creator A5085894866 @default.
• W2140257324 creator A5090913495 @default.
• W2140257324 date "2009-10-01" @default.
• W2140257324 modified "2023-09-27" @default.
• W2140257324 title "Pathological Effects of Prostate Cancer Correlate With Neuroendocrine Differentiation and PTEN Expression After Bicalutamide Monotherapy" @default.
• W2140257324 cites W1972092574 @default.
• W2140257324 cites W1972383646 @default.
• W2140257324 cites W1990675767 @default.
• W2140257324 cites W2007558014 @default.
• W2140257324 cites W2024395172 @default.
• W2140257324 cites W2025319771 @default.
• W2140257324 cites W2031646904 @default.
• W2140257324 cites W2050429347 @default.
• W2140257324 cites W2054360084 @default.
• W2140257324 cites W2095541301 @default.
• W2140257324 cites W2109912135 @default.
• W2140257324 cites W2111673712 @default.
• W2140257324 cites W2111752734 @default.
• W2140257324 cites W2112911113 @default.
• W2140257324 cites W2114774008 @default.
• W2140257324 cites W2140382280 @default.
• W2140257324 cites W2156569777 @default.
• W2140257324 cites W4253882649 @default.
• W2140257324 doi "https://doi.org/10.1016/j.juro.2009.06.025" @default.
• W2140257324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19683286" @default.
• W2140257324 hasPublicationYear "2009" @default.
• W2140257324 type Work @default.
• W2140257324 sameAs 2140257324 @default.
• W2140257324 citedByCount "19" @default.
• W2140257324 countsByYear W21402573242012 @default.
• W2140257324 countsByYear W21402573242013 @default.
• W2140257324 countsByYear W21402573242014 @default.
• W2140257324 countsByYear W21402573242015 @default.
• W2140257324 countsByYear W21402573242016 @default.
• W2140257324 countsByYear W21402573242017 @default.
• W2140257324 countsByYear W21402573242018 @default.
• W2140257324 countsByYear W21402573242019 @default.
• W2140257324 countsByYear W21402573242020 @default.
• W2140257324 countsByYear W21402573242021 @default.
• W2140257324 countsByYear W21402573242022 @default.
• W2140257324 crossrefType "journal-article" @default.
• W2140257324 hasAuthorship W2140257324A5016101715 @default.
• W2140257324 hasAuthorship W2140257324A5044840923 @default.
• W2140257324 hasAuthorship W2140257324A5054102028 @default.
• W2140257324 hasAuthorship W2140257324A5077481880 @default.
• W2140257324 hasAuthorship W2140257324A5085894866 @default.
• W2140257324 hasAuthorship W2140257324A5090913495 @default.
• W2140257324 hasConcept C121608353 @default.
• W2140257324 hasConcept C126322002 @default.
• W2140257324 hasConcept C134018914 @default.
• W2140257324 hasConcept C143998085 @default.
• W2140257324 hasConcept C204232928 @default.
• W2140257324 hasConcept C2776166826 @default.
• W2140257324 hasConcept C2776215463 @default.
• W2140257324 hasConcept C2777008409 @default.
• W2140257324 hasConcept C2777609662 @default.
• W2140257324 hasConcept C2777899217 @default.
• W2140257324 hasConcept C2779322244 @default.
• W2140257324 hasConcept C2779466945 @default.
• W2140257324 hasConcept C2779549131 @default.
• W2140257324 hasConcept C2780192828 @default.
• W2140257324 hasConcept C2780341458 @default.
• W2140257324 hasConcept C2780962315 @default.
• W2140257324 hasConcept C502942594 @default.
• W2140257324 hasConcept C530470458 @default.
• W2140257324 hasConcept C55493867 @default.
• W2140257324 hasConcept C61367390 @default.
• W2140257324 hasConcept C62478195 @default.
• W2140257324 hasConcept C71924100 @default.
• W2140257324 hasConcept C77231918 @default.
• W2140257324 hasConcept C86554907 @default.
• W2140257324 hasConcept C86803240 @default.
• W2140257324 hasConceptScore W2140257324C121608353 @default.
• W2140257324 hasConceptScore W2140257324C126322002 @default.
• W2140257324 hasConceptScore W2140257324C134018914 @default.
• W2140257324 hasConceptScore W2140257324C143998085 @default.
• W2140257324 hasConceptScore W2140257324C204232928 @default.
• W2140257324 hasConceptScore W2140257324C2776166826 @default.
• W2140257324 hasConceptScore W2140257324C2776215463 @default.
• W2140257324 hasConceptScore W2140257324C2777008409 @default.
• W2140257324 hasConceptScore W2140257324C2777609662 @default.
• W2140257324 hasConceptScore W2140257324C2777899217 @default.
• W2140257324 hasConceptScore W2140257324C2779322244 @default.
• W2140257324 hasConceptScore W2140257324C2779466945 @default.
• W2140257324 hasConceptScore W2140257324C2779549131 @default.
• W2140257324 hasConceptScore W2140257324C2780192828 @default.
• W2140257324 hasConceptScore W2140257324C2780341458 @default.
• W2140257324 hasConceptScore W2140257324C2780962315 @default.
• W2140257324 hasConceptScore W2140257324C502942594 @default.
• W2140257324 hasConceptScore W2140257324C530470458 @default.
• W2140257324 hasConceptScore W2140257324C55493867 @default.
• W2140257324 hasConceptScore W2140257324C61367390 @default.

• next